Dashboard
Manage Tickers

KTRA TuHURA Biosciences, Inc./NV

Nasdaq tuhurabio.com


$ 1.59 $ -0.17 (-9.43 %)    

Thursday, 20-Nov-2025 15:55:30 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 586.53 $ -14.20 (-2.37 %)
DIA $ 458.63 $ -3.66 (-0.79 %)
SPY $ 653.48 $ -10.10 (-1.52 %)
TLT $ 89.27 $ 0.35 (0.39 %)
GLD $ 374.83 $ -0.11 (-0.03 %)
$ 1.585
$ 1.81
$ 1.59 x 189
$ 1.61 x 500
$ 1.58 - $ 1.83
$ 1.56 - $ 7.20
287,598
na
2.93M
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 10-07-2024 06-30-2024 10-K
7 05-14-2024 03-31-2024 10-Q
8 02-14-2024 12-31-2023 10-Q
9 11-13-2023 09-30-2023 10-Q
10 09-18-2023 06-30-2023 10-K
11 05-11-2023 03-31-2023 10-Q
12 02-14-2023 12-31-2022 10-Q
13 11-09-2022 09-30-2022 10-Q
14 09-27-2022 06-30-2022 10-K
15 05-13-2022 03-31-2022 10-Q
16 02-11-2022 12-31-2021 10-Q
17 11-15-2021 09-30-2021 10-Q
18 09-28-2021 06-30-2021 10-K
19 05-13-2021 03-31-2021 10-Q
20 02-12-2021 12-31-2020 10-Q
21 11-12-2020 09-30-2020 10-Q
22 09-18-2020 06-30-2020 10-K
23 05-13-2020 03-31-2020 10-Q
24 02-13-2020 12-31-2019 10-Q
25 11-13-2019 09-30-2019 10-Q
26 09-09-2019 06-30-2019 10-K
27 05-14-2019 03-31-2019 10-Q
28 02-11-2019 12-31-2018 10-Q
29 11-13-2018 09-30-2018 10-Q
30 09-24-2018 06-30-2018 10-K
31 05-15-2018 03-31-2018 10-Q
32 02-14-2018 12-31-2017 10-Q
33 11-09-2017 09-30-2017 10-Q
34 09-27-2017 06-30-2017 10-K
35 05-12-2017 03-31-2017 10-Q
36 02-10-2017 12-31-2016 10-Q
37 11-10-2016 09-30-2016 10-Q
38 09-13-2016 06-30-2016 10-K
39 05-12-2016 03-31-2016 10-Q
40 02-12-2016 12-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

trading-halt-halted-at-75000-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:50:00 p.m. ET - ...
10/17/2024 23:50:04

kintara-therapeutics-announces-correction-to-prior-announcement-regarding-1-for-35-reverse-stock-split-in-connection-with-proposed-merger-with-tuhura-biosciences-trading-to-begin-under-new-symbol-hura-on-october-18-2024
Kintara Therapeutics Announces Correction ...
10/16/2024 16:56:49

kintara-therapeutics-announces-1-for-35-reverse-stock-split-in-connection-with-proposed-merger-with-tuhura-biosciences-trading-to-begin-under-new-name-and-symbol-hura-on-october-17-reducing-outstanding-shares-to-16m
Kintara Therapeutics Announces 1-for-35 Re...
10/16/2024 15:59:39

kintara-therapeutics-issues-correction-regarding-cvr-issuance-timing-for-proposed-merger-with-tuhura-biosciences-now-set-for-immediately-before-reverse-stock-split-merger-expected-to-close-on-october-18-2024
Kintara Therapeutics Issues Correction Reg...
10/15/2024 20:18:02

kintara-therapeutics-announces-record-date-for-contingent-value-rights-issuance-in-connection-with-the-proposed-merger-with-tuhura-biosciences-expected-to-close-on-october-18-2024
Kintara Therapeutics Announces Record Date...
10/14/2024 12:34:06

 Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new so...

kintara-therapeutics-2024-eps-032-up-from-927-yoy-cash-and-cash-equivalents-49m
Kintara Therapeutics 2024 EPS $(0.32) Up F...
10/08/2024 11:16:57

Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the...

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
09/27/2024 20:31:00

why-telesis-bio-shares-are-trading-higher-by-around-110-here-are-20-stocks-moving-premarket
Why Telesis Bio Shares Are Trading Higher ...
09/26/2024 10:31:57

kintara-therapeutics-provides-update-on-rem-001-clinical-study-has-enrolled-4-of-the-10-patients-needed-to-reach-the-minimum-patient-enrollment-to-assess-safety-and-appropriate-phase-3-dose-with-several-other-patients-identified-as-study-candidates-at-kintaras-clinical-sites-no-treatment-related-safety-issues-have-been-identified-to-date-and-assessment-of-the-appropriate-phase-3-dose-is-ongoing
Kintara Therapeutics Provides Update On RE...
09/11/2024 12:34:25

REM-001 Clinical Study UpdateAs of September 10, 2024, the REM-001 study in patients with cutaneous metastatic breast cancer (C...

kintara-therapeutics-to-hold-special-meeting-for-completion-of-proposed-merger-with-tuhura-biosciences
Kintara Therapeutics To Hold Special Meeti...
09/09/2024 12:38:51

Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count

Core News & Articles
TuHURA Biosciences And Kintara Therapeutic...
07/08/2024 10:35:50

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel t...

kintara-therapeutics-and-tuhura-biosciences-provide-update-on-recent-corporate-and-clinical-advancements-and-outline-near-term-milestones
Kintara Therapeutics and TuHURA Bioscience...
07/01/2024 12:37:49

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
06/21/2024 12:08:00

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
06/20/2024 20:31:11

why-quantum-shares-are-trading-lower-by-45-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Quantum Shares Are Trading Lower By 45...
06/18/2024 17:39:53

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
06/18/2024 16:31:11

why-chegg-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket
Why Chegg Shares Are Trading Higher By Aro...
06/18/2024 09:28:13

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
06/13/2024 20:31:04

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
06/04/2024 16:31:07

tuhura-biosciences-and-kintara-therapeutics-announce-phase-1b-trial-of-ifx-20-in-checkpoint-inhibitor-resistant-advanced-merkel-cell-carcinoma-and-cutaneous-squamous-cell-carcinoma-results
TuHURA Biosciences And Kintara Therapeutic...
06/03/2024 12:36:13

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeksEighty percent (80%) of ICI ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION